New findings suggest that miR-23b could be a crucial target in treating DM1, with research revealing its disease-modifying potential. The study conducted in Valencia, Spain on Feb. 25, 2026, showcases the improved muscle delivery and functional advantages of ATX-01. Arthex Biotech, a prominent biotechnology firm specializing in RNA-based therapeutics, is spearheading these revolutionary advancements. The data points towards miR-23b as a significant player in combating DM1, with promising implications for future treatment strategies.
